AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01025466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine transdermal patch
Description: All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
Study NCT01624402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on Stroke and Depression (ESD)
Description: * Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~* Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~* Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~* ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy).
Study NCT01624402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecosystem Focused Therapy (EFT)
Description: 1. EFT offers an action-oriented, new perspective about the subject's recovery;~2. It provides an adherence enhancement structure;~3. It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~4. It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~5. It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities.
Study NCT03900156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: goal-setting
Description: The interviewer will have access to key information from the initial assessment such as details of identified risks. Areas where the participant would like to make changes or improvements will be identified and prioritized, and up to five specific, realistic and achievable goals will be identified.
Study NCT01941251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: navigated Transcranial Magnetic Stimulation
Description: * individualized α frequency~* left DLPFC 110% motor threshold (MT)~* 13-15 sessions for 3 weeks
Study NCT01941251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: navigated Transcranial Magnetic Stimulation
Description: - placebo treatment: sham coil
Study NCT04286334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone augmentation with cad-cam laser-sintered mesh
Description: Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
Study NCT04286334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone augmentation with cad-cam laser-sintered mesh
Description: Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
Study NCT00795769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Given IV
Study NCT00795769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Correlative studies
Study NCT00795769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Ondansetron IV
Study NCT03919591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Challenge virus RSV-A Memphis 37b
Description: Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
Study NCT01216046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: capsule, taken once daily
Study NCT04402983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
Study NCT01216046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: tablet, taken once every 12 hours
Study NCT01216046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-809 placebo
Description: capsule, taken once daily
Study NCT04005456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Supplements and/or medical foods
Description: Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
Study NCT01216046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-770 placebo
Description: tablet, taken once every 12 hours
Study NCT01485302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR228810
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01485302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR228810
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study NCT02738229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Study NCT02738229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02348554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled conditions
Description: The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
Study NCT02348554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free-living conditions
Description: The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
Study NCT01703559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 1.0%
Description: Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
Study NCT01703559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 0.5%
Description: Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
Study NCT01703559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Description: Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
Study NCT01245153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal Balloon Training
Description: Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week
Study NCT01245153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Description: Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
Study NCT01289574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-J9
Description: Cream for twice daily topical application to the face
Study NCT01289574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC-J9
Description: Cream for twice daily topical application to the face
Study NCT04005456 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.
Study NCT02901301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg, IV, q3weeks, Day 1
Study NCT02901301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6mg/kg (8mg loading dose), IV, q3weeks, Day 1
Study NCT02901301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, PO, BID, Day 1-14
Study NCT02901301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80mg/m2 (level 1), IV, q3weeks, Day 1
Study NCT01134861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29
Study NCT01134861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29
Study NCT01134861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area \< 1.7 m2
Study NCT01134861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: 5 mg/m2 i.v. bolus weekly first 5 weeks of RT
Study NCT01134861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 5 mg/m2 i.v. bolus weekly first 5 weeks of RT
Study NCT01134861 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment
Study NCT01134861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
Study NCT01134861 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment
Study NCT01134861 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
Study NCT04438798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: F Group
Description: In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
Study NCT04438798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: H Group
Description: In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
Study NCT04005456 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Food plan
Description: Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)
Study NCT02275013 — intervention group
Intervention type: DRUG
Intervention: Levosimendan
Study NCT01816685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Study NCT02783053 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Metformin vs no metformin
Study NCT03055923 — intervention group
Intervention type: DEVICE
Intervention: The Inflammacheck Device
Description: A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
Study NCT02485314 — intervention group
Intervention type: OTHER
Intervention: Participation
Description: The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
Study NCT04055259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile Health and Wellness Coaching
Description: Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.
Study NCT04055259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
Study NCT04322760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch with Dexmedetomidine Bupivacaine
Description: 10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
Study NCT04322760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Bupivacaine
Description: 10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
Study NCT00585871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 0.1 mg tid
Study NCT00585871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: 25 mg tid
Study NCT05052502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case Management and Follow-up
Description: Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~* Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~* At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions.
Study NCT05052502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management and Follow-up
Description: Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~* Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~* At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions.
Study NCT05052502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reactive focal mass drug administration (rfMDA)
Description: Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials.~For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants.
Study NCT04668521 — intervention group
Intervention type: OTHER
Intervention: OVA360
Description: Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
Study NCT05114369 — intervention group
Intervention type: PROCEDURE
Intervention: Curative surgery
Study NCT02529371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UriCap-RM
Description: UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
Study NCT01805206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of urinary iFABP
Study NCT01805206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of enteral feedings
Study NCT01317823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of cervical status
Description: Assessment of cervical status based on Bishop score versus sonographically measured cervical length
Study NCT03815383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
Study NCT03282981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Topical application of Timolol on non-healing diabetic foot ulcers
Study NCT03282981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non biologically active gel
Description: Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
Study NCT00370370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Injection of intravitreal bevacizumab
Study NCT00370370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab + triamcinolone acetonide
Description: Injection of bevacizumab + triamcinolone acetonide
Study NCT02925936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thyroid facing the anode end of xray machine
Description: Thyroid position: facing the anode end of xray machine
Study NCT02925936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thyroid facing the cathode end of xray machine
Description: Thyroid position: facing the cathode end of xray machine
Study NCT04289259 — intervention group
Intervention type: OTHER
Intervention: TMB assessment
Description: Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
Study NCT02549417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration
Study NCT04325009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab
Description: 1. st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab
Study NCT04325009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab
Description: 1. st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Lipitor 80mg Tab
Study NCT01138371 — intervention group
Intervention type: PROCEDURE
Intervention: LDL Apheresis
Description: LDL Apheresis
Study NCT01811498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01011699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotinamide
Description: Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week).
Study NCT01011699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevelamer
Description: Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week).